Welcome!

News Feed Item

Hard to Treat Depression Patients Recover Completely With Magnetic Therapy

LONDON, July 2, 2013 /PRNewswire/ --


Leading  London Centre  presents first 'real world' UK data, supporting effectiveness of  repetitive Transcranial Magnetic Stimulation  for the treatment of major depression

 

Data from the first 'real-world' treatment audit presented today at The Royal College of Psychiatrists' International Congress 2013 in Edinburgh show that 60% of patients with treatment-resistant depression achieved complete remission (patients report and show no symptoms) when treated with repetitive Transcranial Magnetic Stimulation (rTMS).[1] These data are in-line with results reported in major treatment centres in the US and Canada.

Results from the 'real-world' audit of the first ten UK patients to be treated with rTMS at The London Psychiatry Centre, showed that six of the ten patients assessed achieved no anxiety or depression symptoms at the end of the treatment. Furthermore, one other patient responded to treatment as indicated by a 50% reduction in their depression score. All patients tolerated the treatments well with no significant side effects, with two subjects reporting an occasional mild headache, responding to paracetaomol.[1]  

Dr Rafael Euba, Consultant Psychiatrist at the Centre said, "These data reinforce the body of existing worldwide evidence for rTMS and its proven ability to treat depressed patients who have not responded to drug treatment and/or therapy."

rTMS is a painless and non-invasive method of brain stimulation that relies on electromagnetic induction using an insulated coil placed over the scalp, focused on an area of the brain thought to play a role in mood regulation.[2] Treatment with rTMS is licenced in the UK for adults with depression who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode. For these patients, rTMS provides an effective and pain-free alternative to experience relief from depression, without the side-effects that may be associated with more extreme or chemical alternatives.[3],[4],[5],[6],[7] Offered widely at high profile hospitals and centres in the US, including John Hopkins and Harvard's McLean Hospital, The London Psychiatry Centre is the first and only clinic to offer rTMS treatment in the UK.

One of the patients who recently completed the four week treatment said, "The treatment shifted the way I approach problems and almost blocks my negative way of thinking. I feel like the person I used to be 30 years ago! I've got my brain back!" After two weeks of treatment, not only had the patient stopped taking her medication completely, she no longer felt the dread she woke up with every day and decided to start doing new things, feeling optimistic about her future.

Around one in ten people in the UK suffer from depression at some point in their lifetime, which is over six million people, a number equivalent to the entire population of Scotland. More frequently prescribed treatments don't always work or are not suitable, plus their side-effects can cause weight gain, low sex drive and even heart problems. Up to 70% of people with depression will continue to experience symptoms despite taking medication and/or receiving psychotherapy. This is known as treatment-resistant depression, which is very common.

According to larger international clinical studies, one in two patients who were unresponsive to antidepressant medication experience a significant improvement in their depressive symptoms when treated with rTMS, while 1 in 3 experiences recovery.[6] Patients with resistant depression treated with rTMS also benefited from a shorter recovery time of around 4 weeks. This compares to those trying alternative medications that would typically experience improvements in around 6-9 months, if recognised treatment protocols are followed.

A further 13 patients have been treated with rTMS since the audit presented today, with all of them achieving complete remission within 4 weeks.  An audit of all 23 patients treated showed that 78% of the patients treated at The London Psychiatry Centre with rTMS achieved complete remission, a further 9% improved but did not achieve remission and 13% did not improve.[8]

If you or a person you know would like to find out more information about treatment with rTMS visit The London Psychiatry website at http://www.psychiatrycentre.co.uk.

Notes to Editors

About depression

Around one in ten people in the UK suffer needlessly from depression at some point in their lifetime and it is thought that a large number of people are still undiagnosed. The condition can impact every aspect of a person's life including their ability to work, establish and maintain relationships and their overall quality of life. Depression has also been associated with an increased risk of cardiovascular disease, such as heart attack and stroke.[9],[10],[11],[12]

About rTMS

rTMS is a non-invasive method of brain stimulation that relies on electromagnetic induction using an insulated coil placed over the scalp, focused on an area of the brain thought to play a role in mood regulation.[13] The coil generates brief magnetic pulses, which pass easily and painlessly through the skull and into the brain. The pulses generated are comparable to those generated by magnetic resonance imaging (MRI) machines. When these pulses are administered in rapid succession, it is referred to as "repetitive TMS " or "rTMS", which can produce longer lasting changes in brain activity.[4]Clinical studies have consistently shown that rTMS is effective in treatment-resistant depression,[6],[14],[15],[16],[17],[18],[19],[20].rTMS has been licensed in the UK to treat patients with depression who have not seen a satisfactory response to 2 antidepressants.

In comparison to more extreme alternatives such as electroconvulsive therapy (ECT), rTMS is considerably less invasive, has minimal side effects,[21] and has proven to offer equivalent health benefits.[22] rTMS is therefore seen as a safe middle step in people who do not respond to antidepressants, before considering ECT. In the US, rTMS is offered as a standard therapy in a number of high profile health clinics including John Hopkins and the Mayo Clinic.  

rTMS treatment is well tolerated and non-invasive, requiring only five sessions per week for between two to  six weeks, sometimes followed by maintenance or top-up treatment 6 -12 months later.[19],[20] Patients also recover faster in around 4 weeks, compared to those who tried different forms of medication, who took between 6-9 months to see significant improvements. Patients don't need to go to hospital to receive treatment with rTMS; the simple procedure is performed in an outpatient clinic.

About  The London Psychiatry Centre

The London Psychiatry Centre offers an integrated and complete service addressing every need associated with mental health. This includes psychiatric, psychological, therapeutic and social aspects of a patient. Consultant Psychiatrists, Psychologists and Psychotherapists along with nutritionists, coaches, personal trainers and therapists are on site to help.

To find out more information about The London Psychiatry, visit the website - http://www.psychiatrycentre.co.uk.

References

1. Euba R, Poster presented at The Royal College of Psychiatrists' International Congress 2013

2. George M, Taylor J, Baron Short E, The expanding evidence base for rTMS treatment of depression, Current Opinion Psychiatry, 2013,26:13-18

3. O'Reardon JP, Solvason HB, Janicak PG, et al.Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007; 62:1208-1216.

4. Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull 2009; 42:5-38.

5. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 2010; 67:507-516.

6. McDonald WM, Durkalski V, Ball ER, et al.Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. Depress Anxiety 2011; 28:973-980

7. Mantovani A, Pavlicova M, Avery D, et al.Long-term efficacy of repeated daily prefrontal transcranial magnetic stimulation (TMS) in treatment-resistant depression. Depress Anxiety 2012; 29:883-890

8. The London Psychiatry Centre data on file

9. Ludescher B, Machann J, Eschweiler GW, Thamer C, Maenz C, Hipp A, Claussen CD, & Schick F (2011). Active depression is associated with regional adiposity in the upper abdomen and the neck. International journal of psychiatry in medicine, 41 (3), 271-80 PMID: 22073766 [http://www.ncbi.nlm.nih.gov/pubmed/22073766 ]

10. Rubin RR, Gaussoin SA, Peyrot M, DiLillo V, Miller K, Wadden TA, West DS, Wing RR, Knowler WC, & Look AHEAD Research Group (2010). Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetologia, 53 (8), 1581-9 PMID: 20422396 [http://www.ncbi.nlm.nih.gov/pubmed/20422396 ]

11. Rutledge T, Linke SE, Krantz DS, Johnson BD, Bittner V, Eastwood JA, Eteiba W, Pepine CJ, Vaccarino V, Francis J, Vido DA, & Merz CN (2009). Comorbid depression and anxiety symptoms as predictors of cardiovascular events: results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Psychosomatic medicine, 71 (9), 958-64 PMID: 19834049 [http://www.ncbi.nlm.nih.gov/pubmed/19834049 ]

12. Shah AJ, Veledar E, Hong Y, Bremner JD, & Vaccarino V (2011). Depression and history of attempted suicide as risk factors for heart disease mortality in young individuals. Archives of general psychiatry, 68 (11), 1135-42 PMID: 22065529 [http://www.ncbi.nlm.nih.gov/pubmed/22065529 ]

13. George M, Taylor J, Baron Short E, The expanding evidence base for rTMS treatment of depression, Current Opinion Psychiatry, 2013,26:13-18

14. Li CT, Wang SJ, Hirvonen J, et al. Antidepressant mechanism of add-on repetitive transcranial magnetic stimulation in medication-resistant depression using cerebral glucose metabolism. J Affect Disord. 2010, 127(1-3):219-29

15. Blumberger DM, Mulsant BH, Fitzgerald PB, et al. A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. World J Biol Psychiatry. 2012;13(6):423-35

16. Fitzgerald PB, Hoy K, Gunewardene R, et al. A randomized trial of unilateral and bilateral prefrontal cortex transcranial magnetic stimulation in treatment-resistant major depression. Psychol Med. 2010;41:1187-1196

17. Galletly C, Gill S, Clarke P, Burton C, Fitzgerald PB. A randomized trial comparing repetitive transcranial magnetic stimulation given 3 days/week and 5 days/week for the treatment of major depression: is efficacy related to the duration of treatment or the number of treatments? Psychol Med. Sep 13 2011:1-8.

18. Holtzheimer PE, 3rd, McDonald WM, Mufti M, et al. Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression. Depress Anxiety. Oct 2010;27(10):960-963.

19. Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook IA, Dunner DL, Lanocha K, Solvason HB, Demitrack MA. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012;29(7):587-96.

20. Connolly KR, Helmer A, Cristancho MA, Cristancho P, O'Reardon JP. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. J Clin Psychiatry. 2012;73(4):e567-73.

21. Eranti S, Mogg, et al. [http://www.ncbi.nlm.nih.gov/pubmed/17202547 ] A Randomized, Controlled Trial with 6-Month Follow-Up of Repetitive Transcranial Magnetic Stimulation and Electroconvulsive Therapy for Severe Depression". American Journal of Psychiatry, 2007164 (1): 73-81

22. Coverage Policy Analysis: Repetitive Transcranial Magnetic Stimulation (rTMS), The New England Comparative Effectiveness Public Advisory Council, completed by: The Institute for Clinical and Economic Review. June 2012

SOURCE The London Psychiatry Centre

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Akana has announced the availability of version 8 of its API Management solution. The Akana Platform provides an end-to-end API Management solution for designing, implementing, securing, managing, monitoring, and publishing APIs. It is available as a SaaS platform, on-premises, and as a hybrid deployment. Version 8 introduces a lot of new functionality, all aimed at offering customers the richest API Management capabilities in a way that is easier than ever for API and app developers to use.
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
DevOps at Cloud Expo, taking place Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long dev...
Is the ongoing quest for agility in the data center forcing you to evaluate how to be a part of infrastructure automation efforts? As organizations evolve toward bimodal IT operations, they are embracing new service delivery models and leveraging virtualization to increase infrastructure agility. Therefore, the network must evolve in parallel to become equally agile. Read this essential piece of Gartner research for recommendations on achieving greater agility.
Personalization has long been the holy grail of marketing. Simply stated, communicate the most relevant offer to the right person and you will increase sales. To achieve this, you must understand the individual. Consequently, digital marketers developed many ways to gather and leverage customer information to deliver targeted experiences. In his session at @ThingsExpo, Lou Casal, Founder and Principal Consultant at Practicala, discussed how the Internet of Things (IoT) has accelerated our abil...
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
With so much going on in this space you could be forgiven for thinking you were always working with yesterday’s technologies. So much change, so quickly. What do you do if you have to build a solution from the ground up that is expected to live in the field for at least 5-10 years? This is the challenge we faced when we looked to refresh our existing 10-year-old custom hardware stack to measure the fullness of trash cans and compactors.
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
The emerging Internet of Everything creates tremendous new opportunities for customer engagement and business model innovation. However, enterprises must overcome a number of critical challenges to bring these new solutions to market. In his session at @ThingsExpo, Michael Martin, CTO/CIO at nfrastructure, outlined these key challenges and recommended approaches for overcoming them to achieve speed and agility in the design, development and implementation of Internet of Everything solutions wi...
With over 720 million Internet users and 40–50% CAGR, the Chinese Cloud Computing market has been booming. When talking about cloud computing, what are the Chinese users of cloud thinking about? What is the most powerful force that can push them to make the buying decision? How to tap into them? In his session at 18th Cloud Expo, Yu Hao, CEO and co-founder of SpeedyCloud, answered these questions and discussed the results of SpeedyCloud’s survey.
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
To leverage Continuous Delivery, enterprises must consider impacts that span functional silos, as well as applications that touch older, slower moving components. Managing the many dependencies can cause slowdowns. See how to achieve continuous delivery in the enterprise.
Actian Corporation has announced the latest version of the Actian Vector in Hadoop (VectorH) database, generally available at the end of July. VectorH is based on the same query engine that powers Actian Vector, which recently doubled the TPC-H benchmark record for non-clustered systems at the 3000GB scale factor (see tpc.org/3323). The ability to easily ingest information from different data sources and rapidly develop queries to make better business decisions is becoming increasingly importan...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Kubernetes, Docker and containers are changing the world, and how companies are deploying their software and running their infrastructure. With the shift in how applications are built and deployed, new challenges must be solved. In his session at @DevOpsSummit at19th Cloud Expo, Sebastian Scheele, co-founder of Loodse, will discuss the implications of containerized applications/infrastructures and their impact on the enterprise. In a real world example based on Kubernetes, he will show how to ...